News

The Pure Jamaican Group of Companies (Pure Jamaican), including the pharmaceutical division Seven-10 based in Montego Bay, and Klaria Pharma Holding AB (Klaria), a Swedish pharmaceutical firm listed on NASDAQ First North (KLAR.ST), announced today that they have established an exclusive agreement to conduct R&D and to commercialize their offerings, across all of the LAC region (Latin America and Caribbean Region, which is defined as Mexico, Central America, South America and the Caribbean). The ground-breaking offering is a patented revolutionary, pharmaceutical, precision-dose delivery system for psilocybin to support global advancements in mental health science. The announcement comes on the eve of the CanEx Jamaica Psychedelics Summit to be held in Jamaica on July 15-16, 2021.

With leadership and backing from medicinal cannabis industry veterans in the US, Canada, Jamaica, Mexico, and Israel, Pure Jamaican is building out pharmaceutical manufacturing operations, an R&D innovation center, and a global supply chain of plant-derived pharmaceutical molecules, including cannabinoids and psilocybin, in Jamaica. Pure Jamaican will combine large-scale GACP botanical production across three Parishes in Jamaica with world-class EU GMP pharmaceutical manufacturing in Montego Bay to produce premium quality cannabinoid Active Pharmaceutical Ingredients (APIs) and select pharma-grade finished goods at scale for export to major pharmaceutical and consumer packaged goods (CPG) customers in all legal markets around the world.

Klaria develops products based on the company’s patented Alginate Film delivery system which enables rapid and precise delivery of APIs across the oral mucosa. In so doing, Klaria’s technology can replace nasal sprays and injections with a superior delivery system. Klaria is developing a pipeline of pharmaceutical projects, including treatments for migraines and anaphylactic shock. This partnership with Pure Jamaican enables manufacturing and will create distribution networks and international sales of Alginate Film products containing psilocybin for mental health applications. Previously the companies signed an agreement to conduct R&D and develop a scalable international supply chain for Alginate Filmproducts containing cannabinoid APIs to produce pharmaceutical medicines:

Diane Edwards, President of Jamaica Promotions Corporation (JAMPRO), an Agency of the Government of Jamaica (GOJ) promoting Jamaican business opportunities for export and investment, said, “In our efforts to promote and advance business opportunities in Jamaica by attracting new companies, new products, new technologies and skills for our people, this exclusive partnership between Pure Jamaicanand the Swedish company Klaria Pharma is a strong indication of the increasing attractiveness of Jamaica as an international science and technology hub. Being able to attract new intellectual property to our shores, and to begin building a reputation as a global leader, manufacturer, and exporter of a new pharmaceutical delivery system for medicinal cannabis and psilocybin are exciting economic development opportunities for our country. We look forward to further conversations with Pure Jamaican, Klaria and the leaders of CanEx Jamaica Psychedelics this week.”

The partnership agreement between Pure Jamaican and Klaria enables:

• The research and production of medical grade psilocybin-loaded products in Jamaica, under the regulatory purview of the Pharmacy Council of Jamaica (PCJ) and the Ministry of Health and Wellness (MOHW), for testing and clinical trials;
• Klaria to leverage the R&D and pharmaceutical manufacturing operations of Pure Jamaican, Seven-10 and their affiliated companies in Jamaica for the legal production and loading of pharmaceutical-grade psilocybin and cannabinoid Alginate Films;
• Pure Jamaican-branded psilocybin Alginate Films to be sold in Jamaica and exported as permitted by PCJ and MOHW to CARICOM countries, Latin America including Mexico and Brazil, and other legal jurisdictions globally.

Klaria’s CEO Jesper Wiklund said in making the announcement, “Psilocybin has the potential to fundamentally change the treatment of a range of psychiatric conditions, including depression and Post-Traumatic Stress Disorder (PTSD). Klaria’s patented delivery technology has the potential to dramatically improve the precision and pharmacokinetics of psilocybin administration, as compared to oral delivery which is today the de facto administration method for psilocybin. This exciting partnership with Pure Jamaican, supported by the Government of Jamaica, brings us one step closer to that goal. Not only has Pure Jamaican established extremely high standards for modern botanical cultivation and pharmaceutical science in Jamaica, but they also understand the precise and rigorous requirements in making pharmaceutical products.”

Scott Cathcart, Co-Founder & CEO of Pure Jamaican added, “This is an example of our commitment to bring world-class technology, pharmaceutical manufacturing, and economic opportunity to Jamaica. We are proud to partner with both Klaria and JAMPRO, and to play a leadership role in the global effort to elevate the medical standards for the production, delivery and consumption of cannabinoids, psilocybin, and other plant-derived molecules to come. Klaria’s patented Alginate Film technology is a great delivery system for precision-dosed, pharmaceutical-grade botanicals. The handling of it also requires far more robust levels of production rigor, documentation, testing and regulatory approvals, which are all paths that we are well equipped to follow. We are very impressed with the Klaria technology and, with the requisite approvals from our regulatory agencies within the Government of Jamaica, we look forward to producing pharmaceutical versions with Jamaican cannabinoids and psilocybin for export to legal countries globally.”